Search
3,4-Methylenedioxy-N-isopropylamphetamine
go.drugbank.com/drugs/DB06112ExperimentalMDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF"). … MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).
Synonyms: MDI-P, 3,4-Methylenedioxy-N-isopropylamphetaminePTI-801
go.drugbank.com/drugs/DB05300InvestigationalIt is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.
Acipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox is a niacin derivative used as a hypolipidemic agent. … It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid.
Categories: Heterocyclic Compounds, 1-RingR450
go.drugbank.com/drugs/DB05469ExperimentalR450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.
Imipramine
go.drugbank.com/drugs/DB00458ApprovedInvestigationalImipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. … TCAs also block histamine H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepineTM5614
go.drugbank.com/drugs/DB16516InvestigationalTM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. … PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome[L31673,A228793,A228798], and current studies are exploring downstream effects of its inhibition.
SF1126
go.drugbank.com/drugs/DB05210InvestigationalSF1126 is an integrin-targeted PI3 kinase inhibitor.
Synonyms: SF 1126, SF-1126Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingEthosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Synonyms: 2-ethyl-2-methylsuccinimide, (±)-2-ethyl-2-methylsuccinimideCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingTetrahydrofolic acid
go.drugbank.com/drugs/DB00116InvestigationalNutraceuticalTetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. … It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.
Categories: Vitamin B Complex, Heterocyclic Compounds, 2-RingAffitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates. … Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.